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CPRD- Clinical Practice Research Datalink
EMR- Electronic medical record
GINA- Global Initiative for Asthma
GP- General practitionerHCRU-Health care resource use
HES- Hospital episode statistics
ICS- Inhaled corticosteroidISAR- International Severe Asthma Registry
OCS- Oral corticosteroidOPCRD-Optimum Patient Care Research Databasean eosinophilic phenotype and asthma severity/health care
resource use (HCRU).
METHODS: Patients age 13 years and older with active
asthma and blood eosinophil count or 1 or greater, who were
included from the Optimum Patient Care Research
Database and the Clinical Practice Research Datalink, were
categorized according to the likelihood of eosinophilic
phenotype using the International Severe Asthma Registry
gradient eosinophilic algorithm. Patient demographic,
clinical and HCRU characteristics were described for each
phenotype.
RESULTS: Of 241,006 patients, 50.3%, 22.2%, and 21.9% most
likely (grade 3), likely (grade 2), and least likely (grade 1),
respectively, had an eosinophilic phenotype, and 5.6% had a
noneosinophilic phenotype (grade 0). Compared with patients
with noneosinophilic asthma, those most likely to have an
eosinophilic phenotype tended to have more comorbidities
(percentage with Charlson comorbidity index of ‡2: 28.2% vs
6.9%) and experienced more asthma attacks (percentage with
one or more attack: 24.8% vs 15.3%). These patients were also
more likely to have asthma that was difficult to treat (31.1% vs
18.3%), to receive more intensive treatment (percentage on
Global Initiative for Asthma 2020 step 4 or 5: 44.2% vs 27.5%),
and greater HCRU (eg, 10.8 vs 7.9 general practitioner all-cause
consultations per year).
CONCLUSIONS: The eosinophilic asthma phenotype
predominates in primary care and is associated with greater
asthma severity and HCRU. These patients may benefit from
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INTRODUCTION
Primary care providers are the front line of asthma manage-
ment and have a crucial role in the early identification and
management of uncontrolled disease. However, asthma remains
poorly controlled and characterized. Many patients are provided
with the umbrella diagnosis of asthma and receive regular asthma
treatment, in accordance with a one-treatment-fits-all, step-up/
step-down, guideline-directed approach, but with little clinical
benefit.1 That is now changing with increased knowledge of the
underlying mechanisms of asthma, identification of numerous
biomarkers of airway inflammation, availability of biologics that
target specific inflammatory pathways, and the switch in focus to
treatable traits. According to the Lancet Asthma Commission,
what is needed is a “third era of asthma management”1 that
considers the heterogeneity of asthma and delivers precision
disease management based on disease characteristics.
Eosinophilic airway inflammation is one such treatable trait,
with several reliable biomarkers (eg, FeNO, blood eosinophil
count [BEC]) that provide information about the risk for asthma
attacks and likely response to inhaled corticosteroids (ICS).2-5
These biomarkers are easy to measure, which makes them
particularly suited for use in primary care. They have been shown
to stratify risk and to facilitate the targeting and economic use of
asthma therapy.2,6,7 Conversely, asthma, which is truly non-
eosinophilic (ie, no eosinophilic airway inflammation without
ICS), tends to be mild in nature and low in risk.8-10 Asthma
phenotyping is specifically recommended at the specialist level.11
Devising a simple way to categorize the primary care asthma
population into those with and without eosinophilic asthma is an
important first step in deconstructing this disease into its com-
ponents and could introduce phenotype-directed precision
treatment earlier in the patient’s journey.
Work has commenced on this deconstruction in primary
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eosinophilic, obese noneosinophilic, and benign asthma. The
eosinophilic phenotype cluster was defined according to the
presence of airway dysfunction, symptoms, and elevated FeNO
and sputum eosinophil count. However, use of phenotype-
defining variables not routinely measured (eg, sputum eosino-
phil count, reversibility) or burdensome to the patient (eg, peak
flow variability) may limit the usefulness of these categorizations
in primary care. A Swedish study employed an alternative
approach and used only self-reported asthma characteristics from
1291 asthma patients.12 They also found three distinct pheno-
type clusters: early-onset predominantly female, adult-onset
predominantly female, and adult-onset predominantly male,
the first of which had the highest disease burden.12 However,
what that study gained in accessibility of variables (ie, most pa-
rameters would be available from patients’ electronic medical
records [EMRs]), it lost in terms of a lack of characterization of
the underlying inflammatory pathway.
A combination of phenotypic characteristics and biomarkers
may be a better way to characterize asthma types. This was
recently done to disentangle eosinophil phenotypes in a global,
real-life, adult, severe asthma cohort (ie, International Severe
Asthma Registry [ISAR]).16 The ISAR multicomponent, eosin-
ophil phenotype classification algorithm used variables accessible
at specialist asthma centers as well as primary care and considered
variability in BEC (using the highest recorded value) and the
impact of oral corticosteroids (OCS), both of which can
confound phenotype classification.17
The aims of our study were to (1) reapply the ISAR eosino-
philic gradient algorithm in a broader and more heterogeneous
primary care asthma cohort to quantify and characterize the
eosinophilic phenotypes in this cohort; and (2) assess the rela-
tionship between the likelihood of eosinophilic phenotype
asthma severity and health care resource use (HCRU).
METHODS
Hypothesis
Our hypotheses were that (1) the recently developed ISAR
eosinophil classification algorithm16 would have utility beyond the
severe asthma population and may be applied to a broad primary
care asthma cohort, (2) the prevalence of the asthma eosinophil
phenotype in primary care would be higher than previously thought,
and (3) this eosinophilic phenotype would be associated with greater
disease severity and HCRU.
Study design
This historical cohort study included a broad real-life population
of patients with active asthma, registered at general practitioner (GP)
practices in the United Kingdom. The current study protocol was
approved by Anonymized Data Ethics and Protocol Transparency
Committee 1919, performed in compliance with Good Clinical
Practice and Good Pharmacoepidemiology Practice and registered
with the European Union Electronic Register of Post-Authorization
studies (EUPAS31500) and the Independent Scientific Advisory
Committee (ISAC_19_229).18
Data sources
Data were obtained from the Optimum Patient Care Research
Database (OPCRD)19 and the Clinical Practice Research Datalink
(CPRD). The OPCRD dataset is composed of medical records ofmore than 11 million patients from over 800 general practices across
the United Kingdom (approximately 8% of the total UK
population) and integrates with all UK clinical systems (EMIS, TPP
SystmOne, InPS Vision, and Microtest Evolution). It benefits from
a long retrospective period (median time in the database, is 19.8
years [range, 12.8-25.7 years], going back to birth for summary
diagnostic data in many cases), and contains linked patient-
completed respiratory questionnaires for approximately 10% of
asthma patients included.20 The OPCRD is approved by the UK
National Health Service for clinical research use (Research Ethics
Committee reference 15/EM/0150). The CPRD GOLD database is
an ongoing primary care database of anonymized medical records
from GPs, with coverage of over 11 million patients from 700
practices in the United Kingdom, with a median patient time in the
database of 19.3 years (range, 9.9-25.2 years).21 Only patients
whose data could be linked to Hospital Episode Statistics (HES)
were selected from the CPRD. Both the OPCRD and the CPRD
are well-validated and used frequently for medical and health
research.22,23
Patients
Patients included were aged 13 years and older, with a diagnosis
of active asthma and continuous EMRs for the 12 months before
enrolment. Active asthma was defined as one or more prescription
for an ICS or short-acting ß2-agonist containing inhaler in the past
12 months before enrolment. At least one BEC recording was also
required after the date of first active asthma diagnosis without pre-
scription for OCS or anti-IL-5/5R therapy in the prior 4 weeks. For
HCRU analysis, linkage with CPRD-HES was a requirement. Those
with uncertain information about the age of asthma onset or a
diagnosis of chronic lower respiratory disease other than asthma were
excluded.
Predefined eosinophil phenotypes
Patients were classified using a predefined gradient eosinophilic
algorithm based on the one developed by the expert consensus of
ISAR’s steering committee.14 This group of experts selected vari-
ables based on the evidence and feasibility of availability in real-life
clinical practice. These variables and cutoffs included the highest
recorded BEC, without recent (within 4 months) OCS prescription
(>300, 150-300, or <150 cells/mL), antieIL-5/5R treatment,
history of or current long-term OCS, history of or current diagnosis
of nasal polyps, and late asthma onset (age 30 years) (Figure 1).
FeNO was omitted because of its limited availability in these two
primary care datasets. Phenotypes were classified as grade 3 (most
likely eosinophilic), grade 2 (likely eosinophilic), grade 1 (least likely
eosinophilic), and grade 0 (noneosinophilic). Patients most likely to
have an eosinophilic phenotype (grade 3) were those with the
highest BEC recorded as 300 cells/mL or greater or to be receiving
antieIL-5/5R therapy, or with a BEC of 150 to 300 cells/mL or
greater, (1) receiving long-term OCS or (2) with both nasal polyps
and adult onset. The noneosinophilic phenotype (grade 0) was
defined by experts as highest recorded BEC of less than 150 cells/mL
in the absence of nasal polyps, adult onset, or maintenance OCS.
Figure 1 provides definitions of grade 1 and 2 eosinophilic
phenotypes.
Description of eosinophilic and noneosinophilic
asthma phenotypes
Patient demographic, clinical, and HCRU characteristics were
described and compared according to different likelihoods of
FIGURE 1. Algorithm flowchart showing prevalence of eosinophilic phenotypes within a UK primary care active asthma cohort (Optimum
Patient Care Research Database plus Clinical Practice Research Datalink) (n ¼ 241,006). For blood eosinophil count (BEC), the highest
recorded value was used, without a recent (ie, within 4 months) oral corticosteroid (OCS) prescription.
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predefined date. For OPCRD, this predefined date was the most
recent EMR data extraction from general practice. Because linkage to
HES data was available up to March 1, 2019, the predefined date for
the CPRD was either the date of the most recent EMR extraction
(if extraction was before March 1, 2019) or a randomly chosen date
in the 12 months before March 1, 2019 (if extraction was after
March 1, 2019) (see the full list of variables collected in this article’s
Online Repository at www.jaci-inpractice.org).
Analysis
We used Stata software (version 14.1, College Station, Texas) to
conduct all statistical analyses. The prevalence of predefined eosin-
ophilic phenotypes was determined for the total population
(OPCRD plus CPRD), for OPCRD and CPRD populations sepa-
rately (in subpopulations with information about symptoms ob-
tained during the annual review), and for patients with asthma that
was difficult to treat (severe). Those with severe asthma were defined
as having uncontrolled asthma at Global Initiative for Asthma
(GINA) step 4 or GINA step 5, using the 2020 GINA definitions of
step 4/5 asthma treatment.11 We also performed a sensitivity analysis
to determine eosinophil phenotype distribution in patients who had
a recent assessment of asthma control (ie, within 15 months).
Asthma control was assessed using the three Royal College of Phy-
sicians questions,24 which is a quality of asthma care indicator within
the UK Quality an Outcomes Framework, a voluntary annual
reward and incentive program for all GP surgeries in the United
Kingdom.
Demographics, diagnosed comorbidities, and clinical character-
istics such as asthma therapy and control were described overall and
for the predefined phenotypes, the total population (OPCRD plus
CPRD), those with a recent asthma assessment, and those with
asthma that was difficult to treat (severe). Asthma burden and
HCRU variables were described overall and for the predefinedphenotypes for the CPRD population. Demographic, clinical, and
HCRU variables are described as numbers and prevalence rates per
category for dichotomous and categorical variables. Means (SDs) and
medians (interquartile ranges) as well as categorical distributions are
described for counts and continuous variables. In addition, age-
standardized means and prevalence rates with 95% confidence in-
tervals are reported for predefined phenotypes, using the total pop-
ulation as the standard to account for artificial differences in age
distribution among phenotype groups, caused by selection of the
presence of late-onset asthma.
Pearson’s chi-square tests of independent categories for categorical
variables and nonparametric Kruskal-Wallis equality of populations
rank test for variables on a continuous or ordinal scale were per-
formed to examine the statistical significance of differences in dis-
tribution of characteristics among phenotypes. Relevant differences
in the crude distribution of characteristics between phenotype grade
3 and grades 0, 1, and 2 are reported as the standardized mean
difference (SMD) with grade 3 as the reference. This measure is not
affected by the number of observations and provides information
about the magnitude of differences; thus, it is a better way to judge
relevant differences compared with a P value of a hypothesis test of
difference. The SMD was calculated for both continuous and cate-
gorical variables using the formula shown in Table E1 (in this ar-
ticle’s Online Repository at www.jaci-inpractice.org). We considered
an SMD greater than 10% to indicate a relevant difference. Rate
ratios with 95% confidence intervals comparing HCRU events for
patients with grades 2/3 versus 0/1 were estimated using negative
binomial regression in the total study population. Although prior
sample size planning was not done, we assumed the study to be
adequately powered to detect any difference resulting from the large
sample size. Analyses were adjusted for variables included in the
model that gave a change in coefficient of the association of at least
2%. These variables were age, sex, body mass index, smoking status,
eczema, chronic sinusitis, diabetes, osteoporosis, hypertension,
TABLE I. Demographic and clinical characteristics according to eosinophilic and noneosinophilic phenotype in primary care UK cohort (Optimum Patient Care Research Database plus
Clinical Practice Research Datalink) with active asthma
Variable Grade 0 (n [ 13,521) Grade 1 (n [ 52,741) Grade 2 (n [ 53,431) Grade 3 (n [ 121,313) Total (n [ 241,006) P SMD 0-3 SMD 1-3 SMD 2-3
Sex
Female, n (%) 8533 (63.1) 33,688 (63.9) 36,194 (67.7) 73,709 (60.8) 152,129 (63.1) <.0001 4.8 6.4 14.6
Age at last extraction date, y
Mean (SD) 36.7 (14.1) 46.9 (17.4) 64.0 (13.0) 54.1 (19.4) 53.7 (18.8) <.0001 102.3 39.2 60.1
13-17, n (%) 973 (7.2) 1757 (3.3) 16 (0.0) 4207 (3.5) 6953 (2.9) <.0001 75.0 33.3 36.7
18-64, n (%) 12,008 (88.8) 41,900 (79.4) 27,309 (51.1) 76,588 (63.1) 157,805 (65.5)
65, n (%) 540 (4.0) 9084 (17.2) 26,106 (48.9) 40,518 (33.4) 76,248 (31.6)
Body mass index, kg/m2
n 11,808 48,178 51,182 113,475 224,643 <.0001 25.8 6.4 14.4
Underweight (<18.5),
n (%)
476 (4.0) 1250 (2.6) 668 (1.3) 2956 (2.6) 5350 (2.4)
Normal (18.5 to <25),
n (%)
4454 (37.7) 14,922 (31.0) 11,862 (23.2) 31,748 (28.0) 62,986 (28.0)
Overweight (25 to <30),
n (%)
3752 (31.8) 15,763 (32.7) 17,651 (34.5) 37,594 (33.1) 74,760 (33.3)
Obese (30), n (%) 3126 (26.5) 16,243 (33.7) 21,001 (41.0) 41,177 (36.3) 81,547 (36.3)
Smoking status
n 13,076 51,105 51,747 118,160 234,088 <.0001 28.7 9.2 12.9
Current smoker, n (%) 2179 (16.7) 9367 (18.3) 7508 (14.5) 17,716 (15.0) 36,770 (15.7)
Ex-smoker, n (%) 4115 (31.5) 20,158 (39.4) 26,625 (51.5) 53,541 (45.3) 104,439 (44.6)
Never smoker, n (%) 6782 (51.9) 21,580 (42.2) 17,614 (34.0) 46,903 (39.7) 92,879 (39.7)
Age at asthma onset, y
Mean (SD) 13.0 (8.4) 24.3 (19.5) 49.9 (13.9) 34.2 (22.2) 34.3 (21.9) <.0001 125.5 47.5 84.7
Childhood onset (<18 y),
n (%)
9630 (71.2) 25,455 (48.3) 534 (1.0) 37,808 (31.2) 73,427 (30.5) <.0001 135.5 49.4 110.0
Adult onset (18-29 y),
n (%)
3891 (28.8) 11,446 (21.7) 289 (0.5) 14,824 (12.2) 30,450 (12.6)
Late onset (30 y), n (%) 0 15,840 (30.0) 52,608 (98.5) 68,681 (56.6) 137,129 (56.9)
Comorbidity ever
Eczema, n (%) 3812 (28.2) 14,694 (27.9) 13,128 (24.6) 38,806 (32.0) 70,440 (29.2) <.0001 8.3 9.0 16.5




1013 (7.5) 4716 (8.9) 5576 (10.4) 12,738 (10.5) 24,043 (10.0) <.0001 23.7 19.2 11.6
Chronic rhinosinusitis with
nasal polyps, n (%)
<5 <5 286 (0.5) 3339 (2.8) 3625 (1.5) <.0001
Charlson comorbidity index <.0001 57.7 32.3 11.5
0-1, n (%) 12,583 (93.1) 44,621 (84.6) 35,139 (65.8) 87,151 (71.8) 179,494 (74.5)















































Variable Grade 0 (n [ 13,521) Grade 1 (n [ 52,741) Grade 2 (n [ 53,431) Grade 3 (n [ 121,313) Total (n [ 241,006) P SMD 0-3 SMD 1-3 SMD 2-3





0.2 (0.8) 0.3 (1.0) 0.5 (1.3) 0.5 (1.5) 0.5 (1.3) <.0001 26.3 19.1 5.9
0, n (%) 11,452 (84.7) 43,219 (81.9) 40,879 (76.5) 91,168 (75.2) 186,718 (77.5) <.0001 28.4 20.6 5.3
1, n (%) 1488 (11.0) 6521 (12.4) 7671 (14.4) 17,292 (14.3) 32,972 (13.7)
2, n (%) 347 (2.6) 1641 (3.1) 2334 (4.4) 5687 (4.7) 10,009 (4.2)
3, n (%) 114 (0.8) 603 (1.1) 1018 (1.9) 2572 (2.1) 4307 (1.8)




6878 28,560 31,295 71,236 137,969 .0002 3.3 2.4 0.2
0, n (%) 1986 (28.9) 8228 (28.8) 8818 (28.2) 20,299 (28.5) 39,331 (28.5)
1, n (%) 2810 (40.9) 11,555 (40.5) 12,581 (40.2) 28,307 (39.7) 55,253 (40.0)
2, n (%) 1508 (21.9) 6307 (22.1) 7024 (22.4) 15,827 (22.2) 30,666 (22.2)
3, n (%) 574 (8.3) 2470 (8.6) 2872 (9.2) 6803 (9.5) 12,719 (9.2)
n 6878 28,560 31,295 71,236 137,969 .0002 3.7 2.6 1.3
Poor symptom control,
n (%)
1886 (27.4) 7978 (27.9) 8927 (28.5) 20,735 (29.1) 39,526 (28.6)
n 6878 28,560 31,295 71,236 137,969 <.0001 30.0k 18.1k 2.6
Difficult to treat (GINA
2020), n (%)
1259 (18.3) 6596 (23.1) 9350 (29.9) 22,152 (31.1) 39,357 (28.5)
Lung function
n 1468 8783 16,251 27,419 53,921 <.0001 25.7k 16.3k 5.9
FEV1 % predicted (mean
[SD])
86.9 (20.8) 85.0 (22.4) 82.7 (23.1) 81.3 (22.7) 82.5 (22.7)
n 9758 40,232 44,043 96,778 190,811 <.0001 24.0k 13.6k 1.8
Peak expiratory flow %
predicted (mean [SD])
86.6 (17.9) 84.7 (19.3) 82.4 (21.3) 82.0 (20.5) 82.9 (20.3)
Asthma therapy
GINA 1 (2020), n (%) 2728 (20.2) 7991 (15.2) 4654 (8.7) 11,803 (9.7) 27,176 (11.3) <.0001 43.8k 24.5k 0.4
GINA 2 (2020), n (%) 4890 (36.2) 17,261 (32.7) 15,668 (29.3) 34,324 (28.3) 72,143 (29.9)
GINA 3 (2020), n (%) 2182 (16.1) 9207 (17.5) 9913 (18.6) 21,567 (17.8) 42,869 (17.8)
GINA 4 (2020), n (%) 2499 (18.5) 11,708 (22.2) 13,399 (25.1) 30,434 (25.1) 58,040 (24.1)
GINA 5 (2020), n (%) 1222 (9.0) 6574 (12.5) 9797 (18.3) 23,185 (19.1) 40,778 (16.9)
Inhaled corticosteroid daily
dose,* mg (mean [SD])
170.6 (261.9) 222.0 (297.3) 293.8 (332.0) 274.6 (327.5) 261.5 (320.5) <.0001 35.1k 16.8k 5.8
0, n (%) 2769 (20.5) 8242 (15.6) 5099 (9.5) 12,531 (10.3) 28,641 (11.9) <.0001 45.9k 22.0k 8.5
>0 to <100, n (%) 4796 (35.5) 15,206 (28.8) 11,208 (21.0) 29,804 (24.6) 61,014 (25.3)







































>200-500, n (%) 2612 (19.3) 13,115 (24.9) 17,183 (32.2) 36,093 (29.8) 69,003 (28.6)
>500, n (%) 1060 (7.8) 6062 (11.5) 9038 (16.9) 18,715 (15.4) 34,875 (14.5)
Inhaled corticosteroid
inhalers,† n (mean [SD])
5.3 (6.1) 6.4 (6.5) 8.0 (6.8) 7.3 (6.5) 7.1 (6.6) <.0001 32.0k 13.5k 10.9k
Short-acting b2-agonist daily
dose, mgz (mean [SD])
196.3 (302.2) 235.3 (355.4) 253.2 (403.3) 282.9 (450.0) 261.0 (414.0) <.0001 22.6k 11.8k 7.0
Oral corticosteroid daily dose,
mg (mean [SD])
0.2 (0.9) 0.2 (1.2) 0.3 (1.4) 0.4 (1.7) 0.3 (1.5) <.0001 19.8k 14.1k 6.2
Short-acting muscarinic
antagonist,x n (%)
95 (0.7) 657 (1.2) 1159 (2.2) 2118 (1.7) 4029 (1.7) <.0001 9.5 4.1 3.1
Long-acting muscarinic
antagonist,x n (%)
242 (1.8) 1973 (3.7) 4536 (8.5) 8225 (6.8) 14,976 (6.2) <.0001 24.8k 13.6k 6.4
Long-acting b2-agonist,x
n (%)
350 (2.6) 1557 (3.0) 1949 (3.6) 3931 (3.2) 7787 (3.2) <.0001 3.9 1.7 2.2
Theophylline,x n (%) 76 (0.6) 374 (0.7) 617 (1.2) 1840 (1.5) 2907 (1.2) <.0001 9.4 7.7 3.2
Leukotriene receptor
antagonist,x n (%)
878 (6.5) 3543 (6.7) 3915 (7.3) 10,745 (8.9) 19,081 (7.9) <.0001 8.9 8.0 5.6
GINA, Global Initiative for Asthma; SMD, standardized mean difference.
Grade 0 indicates noneosinophilic; grade 1, least likely eosinophilic; grade 2, likely eosinophilic; and grade 3, most likely eosinophilic (see Figure 1 for a definition of eosinophil phenotype grades). For categorical variables, P values were
calculated using Pearson’s chi-square tests of independent categories.
For continuous or ordinal variables, P values were calculated using nonparametric Kruskal-Wallis equality of populations rank test.
*Fluticasone propionate equivalent (mg).
†For 30 d dispensed in baseline year.
zSalbutamol equivalent (mg).
xOne or more prescription in the past 12 mo (see Table E1 for how to calculate).

































































n (%) (%) n (%) % n (%) % n (%) % n (%) %
300 Blood eosinophil count >
300
Grade 3: most likely 119,477 (49.6) 50.3 66,230 (51.8) 52.6 53,217 (47.0) 47.8 70,077 (50.8) 51.6 21,649 (55.0) 56.3
AntieIL-5/5R Grade 3: most likely 0 0 0 0 0
150 to <300 Long-term OCS Grade 3: most likely 458 (0.2) 277 (0.2) 181 (0.2) 246 (0.2) 246 (0.6)
Presence of nasal polyps
and adult onset (no
long-term OCS)
Grade 3: most likely 1408 (0.6) 702 (0.6) 706 (0.6) 913 (0.6) 257 (0.7)
And nasal polyps (no
long-term OCS)
Grade 2: likely 656 (0.3) 22.0 286 (0.2) 21.8 370 (0.3) 22.2 384 (0.3) 22.5 112 (0.3) 23.5
And adult onset (no long-
term OCS)
Grade 2: likely 52,298 (21.7) 27,604 (21.6) 24,694 (21.8) 30,643 (22.2) 9138 (23.2)
No nasal polyps, adult
onset, or long-term
OCS
Grade 1: least likely 36,901 (15.3) 15.3 18,181 (14.2) 14.2 18,720 (16.5) 16.5 19,603 (14.2) 14.2 4162 (10.6) 10.6
<150 Long-term OCS Grade 2: likely 97 (0.0) 0.2 51 (0.0) 0.2 46 (0.0) 0.2 40 (0.0) 0.2 40 (0.1) 0.3
Adult onset and nasal
polyps (no long-term
OCS)
Grade 2: likely 230 (0.1) 100 (0.1) 130 (0.1) 134 (0.1) 37 (0.1)
Nasal polyps (no long-
term OCS)
Grade 2: likely 150 (0.1) 67 (0.1) 83 (0.1) 94 (0.1) 23 (0.1)
And adult onset (no long-
term OCS)
Grade 1: least likely 15,840 (6.6) 6.6 7694 (6.0) 6.0 8146 (7.2) 7.2 8957 (6.5) 6.5 2434 (6.2) 6.2
No nasal polyps, adult
onset, or long-term OCS
Grade 0: noneosinophilic 13,521 (5.6) 5.6 6666 (5.2) 5.2 6855 (6.1) 6.1 6878 (5.0) 5.0 1259 (3.2) 3.2
AntieIL-5/5R, antieinterleukin 5/5 receptor; GINA, Global Initiative for Asthma; OCS, oral corticosteroids.
*Independent criteria are specified in each row. PreeantieIL-5/5R or long-term OCS was used whenever possible.
†Within the past 15 mo.
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KERKHOF ETAL 4361cardiovascular diseases, anxiety or depression, chronic kidney disease,
apnea, pneumonia and Charlson comorbidity index score.
The best fitting model was determined as follows. For each
association, starting with the crude negative binomial regression
model with the outcome under study and grades as variables, the
biased caused (percent change in the coefficient of grades) when
the candidate confounder was added to the model was assessed for
each candidate separately. After that, the candidate confounders
were added sequentially, sorted by their bias potential in
descending order, and the bias was measured against the previous
model. If the bias was 2% or greater, the candidate was retained in
the model and the next candidate confounder was tested. Age,
body mass index, and Charlson comorbidity index score were
included in the model as confounders for all outcomes. Additional
identified confounders are reported in Table I for the different
outcomes.
The OPCRD is established and maintained by Optimum Patient
Care Ltd. This study was funded by AstraZeneca and conducted by
the Observational and Pragmatic Research Institute Pte Ltd. The
Observational and Pragmatic Research Institute Pte Ltd, Optimum
Patient Care, and AZ members of the ISAR Steering Committee had
input into the study design, data analysis and interpretation, and
manuscript writing, and are authors of this article in line with In-
ternational Committee of Medical Journal Editors author criteria.RESULTS
Patients
We attempted to maximize study power by drawing the final
sample size from a large potential pool of over 20 million people
in primary care, approximately one-third of the UK population.
From a total of 1,135,808 patients with asthma diagnosis, a BEC
of 1 or greater, and age13 years or older in the OPCRD and
CPRD, 241,006 patients were eligible for inclusion: 127,588
from the OPCRD and 113,148 from the CPRD (see Figure E1
in this article’s Online Repository at www.jaci-inpractice.org).
The final sample size chosen for analysis included patients with
sufficient longitudinal data (ie, >12 months), with active asthma
(ie, at least one inhaler prescription in the past year), with suf-
ficient information to categorize the phenotype according to the
eosinophil gradient algorithm (ie, a BEC of at least 1 without
OCS and age of asthma onset), and with no other chronic lower
respiratory conditions (which may have confounded results).
Dates of last data collection (or random date before March 1,
2019 for CPRD data extracted after March 1, 2019) from
general practices ranged from 2008 to 2019; almost half of the
data were uploaded in 2019 and 79% were in the last 5 years (see
Figure E2 in this article’s Online Repository at www.jaci-
inpractice.org). Mean age was 53.7 years (SD, 18.8 years);
63.1% of patients were female, 15.7% were current smokers, and
69.6% were either overweight or obese (Table I). First asthma
diagnosis was recorded at a median age of 35 years (see Figure E3
in this article’s Online Repository at www.jaci-inpractice.org).
Blood eosinophil count distribution
Almost half of patients (49.6%) had the highest BEC recorded
of greater than 300 cells/mL, 38.1% had an intermediate BEC
(150-300 cells/mL), and 12.4% had a low BEC (<150 cells/mL)(Figure 2, A). The presence of nasal polyps was associated with a
higher BEC for all age groups (Figure 2, B).
Eosinophil phenotype characterization
A total of 50.3% of patients were identified as most likely
(grade 3) to have an eosinophilic phenotype, almost all based
on the presence of a BEC greater than 300 cells/mL at any
time during follow-up (Figure 1 and Table II). Moreover,
22.2% of patients were likely (grade 2) and 21.9% were least
likely (grade 1) to have an eosinophilic phenotype (Figure 1
and Table II). Almost all patients classified as likely eosino-
philic had late-onset asthma and a highest BEC in the range of
150 to 300 cells/mL, without nasal polyps. Most patients
classified as least likely eosinophilic had a highest BEC of 150
to 300 cells/mL with no other feature of eosinophilic disease.
The remaining patients had late-onset disease with a low BEC
(<150 cells/mL). In addition, 5.6% of patients had non-
eosinophilic asthma (grade 0). These phenotype classifications
were validated by cross-examining their defining characteris-
tics, which showed an increase in BEC, age at onset, incidence
of nasal polyps, and long-term use of ICS, from grade
0 (noneosinophilic) to grade 3 (most-likely eosinophilic)
phenotypes (see Table E2 in this article’s Online Repository at
www.jaci-inpractice.org).
A similar pattern of most likely eosinophil phenotype pre-
dominance was noted in the OPCRD (52.6%) and CPRD
populations (47.8%), those with a recent asthma assessment
(51.6%) and those with severe asthma (56.3%), with the treat-
ment step defined according to GINA 2020 (Table II). Patients
who had a recent assessment of symptoms during annual review
of asthma were more frequently defined as most likely to have an
eosinophilic phenotype compared with those who were not
recently reviewed (51.6% vs 48.6%) (Figure 3, A). A greater
proportion of severe asthma patients had an eosinophilic
phenotype compared with those without severe disease (56.3%
vs 49.8% using GINA 2020 treatment steps to define severity)
(Figure 3, B).
Demographic and clinical characteristics
Compared with patients with noneosinophilic asthma, those
who most likely had an eosinophilic phenotype were significantly
(all P< .0001, nonparametric Kruskal-Wallis) more likely to have
a comorbidity (eg, the percentage with a Charlson comorbidity
index score of2: 28.2% vs 6.9%) and to experiencemore asthma
attacks (eg, the percentage with one or more attacks: 24.9% vs
15.3%). They were also significantly (all P< .001, nonparametric
Kruskal-Wallis) more likely to have asthma that was difficult to
treat (31.1% vs 18.3%) and to receive more intensive treatment
(eg, with GINA 2020 step 4 or 5 treatment: 44.2% vs 27.5%)
(Table I and Figure 4). Age-standardized means and prevalence
rates showed a gradient increase in asthma attack rates, asthma
control score, symptoms, asthma severity, comorbidities, and in-
tensity of asthma treatment with an increasing likelihood of
eosinophilic phenotype (Figure 5, A and Tables E3-E5, in this
article’s Online Repository at www.jaci-inpractice.org). Results
were similar in those with a recent asthma assessment (see Table E6
in this article’s Online Repository at www.jaci-inpractice.org) and
for those with severe asthma, with treatment steps defined
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Repository at www.jaci-inpractice.org).
Health care resource use
Many HCRU variables assessed showed an increase in HRCU
along the eosinophil phenotype gradient in the total population
(Table III and Figure 5, B; see Table E8 in this article’s Online
Repository at www.jaci-inpractice.org). An increase in relative risk
(RR) from grade 0/1 to grade 2/3 was particularly evident for GP
consultations, outpatient visits, accident and emergency atten-
dances, respiratory hospital admissions, and length of respiratory
overnight stay, and was even more apparent in those with severe
asthma (Table III). For example, patients at grade 2/3 of the
eosinophilic spectrum had a 32% higher risk for a hospital
admission with asthma as the primary diagnosis compared with
those at grade 0/1 (adjusted RR ¼ 1.32 (95% confidence interval
[CI], 1.10-1.59; P¼ .003). The unadjusted RR was slightly lower
but still statistically significant (unadjusted RR ¼ 1.21 (95% CI,
1.02-1.44; P¼ .027). Conversely, patients at grade 2/3 had a 25%
reduced risk for having one or more overnight hospital stay
compared with those at grade 0/1 (adjusted RR ¼ 0.75 (95% CI,
0.62-0.91; P ¼ .004) or a 10% reduced risk for the unadjusted
analysis (unadjusted RR ¼ 0.90; 95% CI, 0.75-1.08; P ¼ .254).
All P values for RR were calculated using negative binomial
regression. Patients at grade 2 or 3 (with difficult-to-treat asthma)
hospitalized for asthma had a mean hospital stay of 6 to 7 days,
compared with 10 days for those at grade 0 or 1 (see Table E9 in
this article’s Online Repository at www.jaci-inpractice.org), a
pattern also seen in the total HCRU population (Table E3).
DISCUSSION
Using a multicomponent eosinophil classification algorithm
modified for use in primary care and a broad primary care asthma
cohort, we classified patients into four groups along a gradient of
eosinophilic phenotype likelihood, from noneosinophilic to most
likely. We showed an associated greater likelihood of having
asthma attacks, reduced lung function (despite a significantly
greater treatment burden, particularly ICS and OCS burden),
and greater HCRU along this gradient. We demonstrated that
the eosinophilic asthma phenotype is prevalent in UK primary
care, and the noneosinophilic phenotype is rare. Notably, this
eosinophilic phenotype was apparent in those with severe asthma
(56.3% of patients) as well as in those with nonsevere asthma
(49.8%). Finally, we described each of these phenotypes using
variables readily available in primary care (using both inflam-
matory indices and disease characteristics), applying the algo-
rithm for use in populations beyond severe asthma, and
confirmed its robustness in a sufficiently large population
generalizable to the primary care asthma population in the
United Kingdom.
After decades of modest advancements in the understanding of
asthma, we are now in the midst of the era of asthmamanagement,
which has provided a greater understanding of the underlying
pathophysiology of asthma, recategorized and reclassified asthma
into different types, and concomitantly delivered new ways to test
and treat these different types. This ongoing revolution in how
asthma is defined and treated necessitates a clear and pragmatic
way forward to guide physicians in primary care, where most
asthma patients are provided with a diagnosis and managed.
Identification of those with an eosinophilic phenotype is impor-
tant because these patients have a relatively high risk for asthmaattacks (even those with mild asthma) and an increased risk for
readmission to hospital.4,25,26 In addition, although eosinophilic
asthma generally responds to corticosteroids, a subgroup of pri-
mary care patients with insufficient response to standard inhaler
treatment regimens (failing GINA step 4) frequently experiences
exacerbations and rapid lung function decline. These patients
should be identified and categorized in primary care; they require
careful follow-up and may benefit from appropriate referral and
early intervention with targeted therapy. Currently, international
asthma management guidelines provide little guidance regarding
phenotyping patients with asthma in primary care. It is seen as the
purview of specialists.11
The multicomponent eosinophil phenotype classification
algorithm described in the current study was based on that used
to describe eosinophilic phenotypes in ISAR, a global, real-life
severe asthma cohort.16 This algorithm, which is based on a
combination of clinical characteristics and biomarkers, may be
a better way to characterize asthma types. Global Initiative for
Asthma also recommends using different combinations of fac-
tors to identify type 2 inflammatory phenotypes, including
BEC, FeNO, sputum eosinophils, the need for maintenance
OCS, and the presence of multiple comorbidities.27 Such a
combination approach arguably affords a more practical means
to determine eosinophilic asthma status compared with reliance
on protracted, sequential BEC.28 Our algorithm was based on
an extensive literature review and expert consensus; it uses
variables readily accessible in primary care, and considers
variability in BEC (using the highest recorded value) and
impact of OCS, both of which can confound phenotype clas-
sification.16,17,29 However, some modifications were made to
apply it to a primary care cohort. For example, elevated FeNO
was not included because this is not routinely measured, and
late-onset asthma (>30 years) was used instead of adult onset
(>18 years), because age at onset is used as a predictor of
response to anti-IL-5. These modifications to the ISAR algo-
rithm are unlikely to have altered our findings, because the
removal of FeNO and adult onset from the algorithm did not
alter findings in the ISAR cohort.16 When this algorithm was
applied to a UK primary care population, approximately 50%
of patients were most likely have an eosinophilic asthma
phenotype, a finding confirmed in both the OPCRD (52.6%)
and CPRD (47.8%). The slightly lower eosinophil phenotype
prevalence in the CPRD was most likely driven by lower
recorded numbers of counts and shorter duration of follow-up
compared with OPCRD counts.
The eosinophilic phenotype existed across the spectrum of
asthma severity (severe: 56.3%; not severe: 49.8%), indicating
that eosinophilic asthma may be present even in mild to mod-
erate disease, and/or that severity may be inappropriately classi-
fied in primary care. A recent study found that large numbers of
asthma patients in the United Kingdom with potential severe
asthma (8%) are effectively hidden in primary care.30 In either
case, a structured assessment by primary care physicians is war-
ranted, with referral to specialist care when appropriate. The
utility of our eosinophil gradient algorithm lies in identifying
these patients (using clinical characteristics and biomarker con-
centrations routinely recorded in primary care), who may benefit
most. Whether these patients have a better prognosis is the next
logical clinical question, and one that merits further study. As
expected, the prevalence of the eosinophilic asthma phenotype
was lower than that recently estimated in a severe asthma cohort
FIGURE 2. (A) Highest blood eosinophil count (BEC) ever distribution and (B) BEC distribution in those with nasal polyps stratified by age,
in a UK primary care cohort of patients with active asthma (Optimum Patient Care Research Database plus Clinical Practice Research
Datalink) (n ¼ 241,006). Blood eosinophil count is expressed as cells per microliter; the highest BEC recorded was used, without recent
(ie, within 4 months) oral corticosteroid prescription.
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asthma population, including those with severe and nonsevere
disease. However, in the current study, the sensitivity of the al-
gorithm was shown by the greater likelihood of eosinophilic
phenotype in patients with severe asthma. We also found a low
prevalence of noneosinophilic asthma in UK primary care
(5.6%), a finding that appears to be independent of disease
severity. It was also low in ISAR (1.6%)16 and other severe
asthma cohorts31 and likely reflects OCS overtreatment.Compared with patients with noneosinophilic asthma, those
who were most likely eosinophilic had a different phenotype;
they were more obese and were more likely to have a comor-
bidity, which is in agreement with findings in the severe asthma
ISAR cohort.16 Although it is unlikely that eczema, allergic
rhinitis, and chronic rhinosinusitis (with or without nasal polyps)
were iatrogenic, other comorbidities may have been (eg, gastro-
esophageal reflux disease, osteoporosis, hypertension, anxiety or
depression) (Table E3).
FIGURE 3. Distribution of grades of eosinophilic asthma in a UK primary care cohort (Optimum Patient Care Research Database plus
Clinical Practice Research Datalink) (A) with (n ¼ 137,969) and without (n ¼ 103,037) a recent assessment of symptoms, and (B) in a
subgroup of patients with (n ¼ 39,357) and without (n ¼ 201,649) severe asthma. Severe asthma was defined as patients at Global
Initiative for Asthma (GINA) step 5 treatment or with uncontrolled asthma at GINA step 4, in which steps 4 and 5 were defined according
GINA 2020 guidelines.11
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eosinophilic phenotype had the most severe disease; they expe-
rienced on average more than twice the asthma attacks per year
and had worse lung function and markedly higher treatment
burden. Notably, the mean daily ICS dose was about 60% higher
in the most likely eosinophilic phenotype group (vs non-
eosinophilic), the daily OCS dose was doubled, and the
proportion of patients at GINA step 4 treatment and above was
higher (44.2% vs 27.5%). This is an important finding consid-
ering that a greater systemic corticosteroid dose has been corre-
lated with a greater cumulative incidence of adverse events and
greater HCRU. It also points to the increasing likelihood of
significant overtreatment as one moves up the eosinophilicphenotype gradient.32 That over a quarter of patients with
noneosinophilic asthma were treated at GINA step 4 and above
(27.5%) indicates that many were likely overtreated; this is an
issue well-recognized by others, including Refractory Asthma
Stratification Project UK. Interestingly, biomarker aloneebased
corticosteroid adjustment does not appear to reduce corticoste-
roid load, a finding likely confounded by patient choice not to
follow treatment advice.33 At the other end of the eosinophil
phenotype spectrum, the smoking history for those most likely
and likely to have an eosinophilic phenotype (ie, >60% current
or previous smokers) suggests that some had chronic obstructive
pulmonary disease or asthma chronic obstructive pulmonary
disease overlap, although almost half of those with
FIGURE 4. Spider plot showing phenotype and endotype variable distribution pattern for eosinophilic (grade 3; n ¼ 80,397) and non-
eosinophilic (grade 0; n ¼ 8067) phenotype in a UK primary care cohort (Optimum Patient Care Research Database plus Clinical Practice
Research Datalink). For blood eosinophil count (BEC), the highest recorded value was used, without recent (ie, within 4 months) oral
corticosteroid prescription. *Clinical Practice Research Datalink database only, grade 0: n ¼ 6855; grade 3: n ¼ 54,104. GINA, Global
Initiative for Asthma 2020; GP, general practitioner; ICS, inhaled corticosteroid; PEF, peak expiratory flow rate.
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adjusted gradient in clinical characteristics was also noted along
the eosinophil phenotype gradient, which was not always visible
in the ISAR cohort, owing to the tightly defined severe asthma
population in the latter. Use of the OPCRD/CRPD primary care
cohort thus allowed us to apply the ISAR algorithm to a broader
patient population and to disentangle phenotypic characteristics
across the gradient, enabling us to see phenotype-associated
treatable traits more clearly.
We also sought to disentangle eosinophilic phenotypes based
on clinical characteristics as well as HCRU, and found an in-
crease in HCRU with increasing likelihood of eosinophilic
phenotype, particularly for outpatient visits and hospital admis-
sions. Compared with those with noneosinophilic asthma, or
patients who were least likely to have an eosinophilic phenotype
(ie, grade 0 or 1), those most likely or likely to have an
eosinophilic phenotype (grade 2 or 3) had 33% more respiratory-
related outpatient visits per year, 18% more respiratory accident
and emergency attendances, and 32% more hospital admissions
with asthma as the primary diagnosis. This increase in HCRU
mirrors the increase in disease severity, treatment, and comor-
bidity burdens across the eosinophil phenotype gradient. We
previously found that HCRU and costs were four times greater
for patients with severe uncontrolled eosinophilic asthma
compared with nonsevere patients with asthma.25 Conversely, we
found a decrease in the duration of hospital stay (with asthma as
a primary diagnosis), moving from left (noneosinophilic) to right
(most likely eosinophilic) across the gradient, perhaps owing to
the rapid steroid responsiveness of most patients with eosino-
philic asthma.
Limitations of this study include reliance on BEC rather than
sputum eosinophilic count, the use of data from the UnitedKingdom only, and the fact that within OPCRD, prescription
data are used to assess treatment burden with the assumptions
that medications were (1) prescribed correctly in line with GINA
2020 recommendations and (2) taken as directed. In addition,
43% of patients ever diagnosed with asthma in the OPCRD had
no BEC available, which may have biased the results. To
counterbalance these limitations, it should be noted that BEC
has been consistently linked to increased risk for asthma attacks
across a range of asthma severities.4,8,34 Furthermore, because of
its combined size, the OPRCD/CPRD enabled us to identify
and study a large cohort of asthma patients, in which large
numbers in each phenotype group provided a balanced repre-
sentation of demographic and clinical characteristics across
groups. The large number of disease-specific variables collected
by these databases facilitated comparison of cohorts using a
comprehensive list of demographic and clinical characteristics.
Although we did not perform power calculations, CIs of rate
ratios (Table III) show that even small increases in variable
prevalence were highly statistically significant, illustrating that
these analyses had sufficient statistical power to find relevant
associations. Finally, our study included a broad heterogeneous
patient population, which removed the issue of selection bias that
may have occurred in the ISAR cohort. Data contained within
the OPCRD and CPRD came from EMRs and were frequently
used for observational research.35-37 These data provide a snap-
shot of patients with asthma managed in real life in practices all
over the United Kingdom.
Asthma phenotype assessment should become part of routine
asthma assessment in primary care. Half of asthma patients in
UK primary care have an eosinophilic asthma phenotype, in
which both disease burden and HCRU increase with an
increasing likelihood of eosinophilic phenotype. The eosinophil
FIGURE 5. (A) Prevalence rates of key asthma variables along eosinophil phenotype gradient (data from Optimum Patient Care Research
Database and Clinical Practice Research Datalink). Grade 0 indicates non-eosinophil (n ¼ 13,521); grade 1, least likely eosinophilic
(n ¼ 52,741); grade 2, likely eosinophilic (n ¼ 53,431; and grade 3, most likely eosinophilic (n ¼ 121,313). Results are presented as
means (95% confidence intervals (CI). (B) Relative risk (RR; 95% CI) to grade 0 for health care resource use variables along eosinophil
phenotype gradient (data from Clinical Practice Research Datalink). For grade 1, n ¼ 26,866; for grade 2, n ¼ 25,323; and for grade 3,
n ¼ 54,104. Grade 0 indicates noneosinophilic; grade 1, least likely eosinophilic; grade 2, likely eosinophilic; and grade 3, most likely
eosinophilic (see Figure 1 for a definition of eosinophil phenotype grades). Rate ratios with 95% CIs and P values were estimated using
negative binomial regression in the total study population. Analyses were adjusted for age, sex, body mass index, smoking status,
eczema, chronic sinusitis, diabetes, osteoporosis, hypertension, cardiovascular diseases, anxiety or depression, chronic kidney disease,
apnea, pneumonia and Charlson comorbidity index score. *P ¼ .0399 versus grade 0. †P ¼ .0044 versus grade 0. zP ¼ .0004 versus
grade 0. xP < .00001 versus grade 0. A&E, accident and emergency; GINA 5, Global Initiative for Asthma Step 5 treatment (2020); GP,
general practitioner; RCP, Royal College of Physicians assessment of asthma control questionnaire.
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step in deconstructing asthma into its component parts, enabling
us to see phenotype-associated treatable traits more clearly and
the opportunity to treat those traits precisely. Routine asthma
phenotyping in general practice may encourage earlier interven-
tion with phenotype-directed treatments and discourage unnec-
essary or inappropriately high steroid doses. Avenues for future
research include an investigation of the impact of early inter-
vention with targeted therapies (eg, biologics that target theeosinophilic phenotype) on disease outcomes and trajectory, and
a test of the implementation of this algorithm as part of quality
improvement in primary care.
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TABLE III. Distribution of health care resource use in total population of asthma patients from: Clinical Practice Research Datalink with hospital episode statistics available
Variable
Grade 0 (n [ 6855)
(mean [SD])
Grade 1 (n [ 26,866)
(mean [SD])
Grade 2 (n [ 25,323)
(mean [SD])
Grade 3 (n [ 54,104)
(mean [SD]) P










7.92 (7.13) 9.21 (8.24) 11.37 (9.54) 10.75 (9.58) <.0001




1-4, n (%) 2324 (33.9) 7765 (28.9) 5062 (20.0) 12,668 (23.4)
5-8, n (%) 1914 (27.9) 7338 (27.3) 6447 (25.5) 14,167 (26.2)
9-11, n (%) 918 (13.4) 3607 (13.4) 3920 (15.5) 7761 (14.3)
12-24, n(%) 1239 (18.1) 6068 (22.6) 7439 (29.4) 14,331 (26.5)




3.78 (4.65) 4.17 (4.73) 4.88 (4.94) 4.53 (4.87) <.0001




1-4, n (%) 2082 (30.4) 7810 (29.1) 7113 (28.1) 15,201 (28.1)
5-8, n (%) 1627 (23.7) 6745 (25.1) 6989 (27.6) 14,385 (26.6)
9-11, n (%) 450 (6.6) 2126 (7.9) 2505 (9.9) 4750 (8.8)
12-24, n (%) 403 (5.9) 1846 (6.9) 2282 (9.0) 4342 (8.0)
25, n (%) 21 (0.3) 112 (0.4) 121 (0.5) 231 (0.4)
All-cause outpatient visits 2.27 (5.53) 2.65 (5.42) 3.49 (6.23) 3.40 (6.39) <.0001




1, n (%) 758 (11.1) 3071 (11.4) 3003 (11.9) 6135 (11.3)
2, n (%) 546 (8.0) 2263 (8.4) 2394 (9.5) 4875 (9.0)
3, n (%) 380 (5.5) 1664 (6.2) 1888 (7.5) 3747 (6.9)
4, n (%) 1332 (19.4) 6432 (23.9) 7904 (31.2) 16,132 (29.8)
Respiratory outpatient visits 0.06 (0.64) 0.07 (0.65) 0.11 (0.72) 0.12 (0.89) <.0001




1, n (%) 61 (0.9) 296 (1.1) 409 (1.6) 856 (1.6)
2, n (%) 30 (0.4) 188 (0.7) 259 (1.0) 498 (0.9)
3, n (%) 17 (0.2) 109 (0.4) 131 (0.5) 346 (0.6)
4, n (%) 31 (0.5) 157 (0.6) 229 (0.9) 523 (1.0)
All-cause accident and
emergency attendances
0.46 (1.28) 0.43 (1.34) 0.42 (1.35) 0.47 (1.27) <.0001




1, n (%) 1181 (17.2) 4484 (16.7) 4086 (16.1) 9401 (17.4)
















































Grade 0 (n [ 6855)
(mean [SD])
Grade 1 (n [ 26,866)
(mean [SD])
Grade 2 (n [ 25,323)
(mean [SD])
Grade 3 (n [ 54,104)
(mean [SD]) P








3, n (%) 149 (2.2) 506 (1.9) 450 (1.8) 1104 (2.0)
4, n (%) 128 (1.9) 455 (1.7) 440 (1.7) 1107 (2.0)
Respiratory accident and
emergency attendances
0.04 (0.46) 0.03 (0.30) 0.04 (0.26) 0.05 (0.32) <.0001




1, n (%) 137 (2.0) 533 (2.0) 648 (2.6) 1515 (2.8)
2, n (%) 12 (0.2) 64 (0.2) 110 (0.4) 257 (0.5)
3, n (%) 6 (0.1) 17 (0.1) 22 (0.1) 46 (0.1)




0.01 (0.23) 0.01 (0.19) 0.01 (0.20) 0.01 (0.23) <0.0001




1, n (%) 37 (0.5) 138 (0.5) 143 (0.6) 451 (0.8)
2, n (%) 8 (0.1) 20 (0.1) 11 (0.0) 62 (0.1)
3, n (%) <5 5 (0.0) 5 (0.0) 9 (0.0)




0.02 (0.28) 0.03 (0.27) 0.04 (0.32) 0.05 (0.36) <.0001




1, n (%) 91 (1.3) 397 (1.5) 601 (2.4) 1489 (2.8)
2, n (%) 12 (0.2) 74 (0.3) 101 (0.4) 232 (0.4)
3, n (%) <5 15 (0.1) 26 (0.1) 63 (0.1)
4, n (%) 5 (0.1) 21 (0.1) 28 (0.1) 74 (0.1)
Length of stay, one or more
overnight asthma
primary
N 36 132 125 414
7.33 (11.31) 6.70 (10.19) 6.47 (10.22) 6.04 (10.08) .5111




2-7, n (%) 18 (50.0) 73 (55.3) 62 (49.6) 228 (55.1)
8-13, n (%) <5 7 (5.3) 25 (20.0) 42 (10.1)
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